Please login to the form below

Not currently logged in
Email:
Password:

IL-13 inhibitor

This page shows the latest IL-13 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Eli Lilly and Almirall’s lebrikizumab shows sustained improvements in atopic dermatitis

Eli Lilly and Almirall’s lebrikizumab shows sustained improvements in atopic dermatitis

The IL-13 inhibitor improved the symptoms of atopic dermatitis for up to two years. ... study of the IL-13 inhibitor.

Latest news

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Twist Health

Not just another healthcare communications agency. We are a collection of award-winning industry experts focusing on bringing the very best...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....